骨感染症のウサギモデルの生成:骨髄に直接細菌を注入して慢性感染を誘発する技術

Executive Industry Relevance

Establishing a reproducible rabbit model of chronic bone infection enables rigorous preclinical evaluation of anti-infective and bone-regenerative therapies. This model addresses the translational gap in osteomyelitis research by providing a controlled system for mechanistic de-risking and therapeutic hypothesis testing. Its relevance spans early discovery through preclinical validation, supporting portfolio decisions in infectious disease and orthopedic R&D.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of infection-driven bone pathology and host response mechanisms.
• Supports biological de-risking by modeling chronic infection and sequestrum formation.
• Facilitates functional validation of anti-infective targets in a disease-relevant system.

Screening & Assay Development

• Provides a validated in vivo platform for quantitative assessment of bacterial burden and bone regeneration.
• Supports standardization of infection induction and readout protocols for reproducibility.
• Enables comparative evaluation of candidate therapeutics under controlled chronic infection conditions.

Translational & Preclinical Research

• Aligns with clinical osteomyelitis features, supporting translational biomarker development.
• Enables continuity from discovery-stage findings to preclinical efficacy and safety studies.
• Informs risk-adjusted advancement of anti-infective and regenerative candidates.

Pipeline & Workflow Integration

This rabbit bone infection model integrates into the discovery-to-preclinical continuum for infectious disease and orthopedic portfolios.

• Discovery Biology: Supports hypothesis testing on infection persistence, immune response, and bone necrosis.
• Screening: Provides a reproducible system for evaluating therapeutic efficacy and infection control.
• Analytics: Enables quantitative measurement of infection progression, sequestrum formation, and treatment response.
• Translational Research: Bridges in vitro findings with in vivo disease relevance for preclinical candidate selection.
• Enterprise Reuse: Offers a standardized, reusable model for cross-program infection and bone healing studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in anti-infective and bone-regenerative candidate selection.
• Operational Value: Standardizes chronic infection induction and monitoring for reproducible outcomes.
• Strategic Value: Reduces late-stage biological risk by enabling robust preclinical validation.
• Portfolio Impact: Supports risk-adjusted prioritization of candidates targeting osteomyelitis and related indications.

Implementation Considerations

• Requires expertise in surgical animal modeling and infection control.
• Needs access to animal facilities, surgical instrumentation, and microbiological infrastructure.
• Demands cross-team standardization of inoculation, monitoring, and readout protocols.
• Adaptation to other species or infection types may require protocol optimization.
• Limitations include species-specific immune responses and ethical considerations in animal use.

Biopharma FAQs